Potential effects of Nicotine on Glioblastoma and Chemoradiotherapy: A Review.

Potential effects of Nicotine on Glioblastoma and Chemoradiotherapy: A Review. Expert Rev Neurother. 2019 May 16;: Authors: McConnell DD, Carr SB, Litofsky NS Abstract INTRODUCTION: Glioblastoma multiforme (GBM) has a poor prognosis despite maximal surgical resection with subsequent multi-modal radiation and chemotherapy. Use of tobacco products following diagnosis and during the period of treatment for non-neural tumors detrimentally affects treatment and prognosis. 16-28% of patients with glioblastoma continue to smoke after diagnosis and during treatment. The literature is sparse for information pertaining effects of smoking and nicotine on GBM treatment and prognosis. Areas covered: This review discusses cellular pathways involved in GBM progression that might be affected by nicotine, as well as how nicotine may contribute to resistance to treatment. Similarities of GBM pathways to those in non-neural tumors are investigated for potential effects by nicotine. English language papers were identified using PubMed, Medline and Scopus databases using a combination of keywords including but not limited to the following: nicotine, vaping, tobacco, e-cigarettes, smoking, vaping AND glioblastoma or brain cancer OR/AND temozolomide, carmustine, methotrexate, procarbazine, lomustine, vincristine, and neural tumor cell lines. Expert Opinion: Understanding the impact of nicotine on treatment and resistance to chemotherapeutics should allow physicians to educate ...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research